DongKook Life Science동국생명과학
303810 · KOSDAQ · ₩303810 · 동국생명과학
₩2,095▼ ₩50 (2.33%)End-of-day · Oct 30, 2026 · End-of-day prices.
Income statement
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Revenue | ₩24B | ₩33B | ₩31B | ₩29B | ₩35B | ₩35B |
| Cost of sales | ₩20B | ₩24B | ₩24B | ₩20B | ₩26B | ₩27B |
| Gross profit | ₩4.5B | ₩8.8B | ₩7.4B | ₩9.1B | ₩8.5B | ₩8B |
| Operating income | ₩22M | ₩3.4B | ₩2.5B | ₩4.3B | ₩3.2B | ₩3.1B |
| Net income | −₩3.2B | ₩2.3B | ₩6.2B | −₩440M | ₩602M | ₩2.2B |
| Net income to shareholders | −₩3.2B | ₩2.3B | ₩6.2B | −₩440M | ₩602M | ₩2.2B |
Balance sheet
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Total assets | ₩218B | ₩224B | ₩218B | ₩209B | ₩206B | ₩203B |
| Current assets | ₩137B | ₩144B | ₩139B | ₩131B | ₩130B | ₩128B |
| Cash and equivalents | ₩5.2B | ₩4.9B | ₩2B | ₩2.7B | ₩2.5B | ₩1.3B |
| Total liabilities | ₩85B | ₩90B | ₩86B | ₩78B | ₩78B | ₩78B |
| Current liabilities | ₩79B | ₩85B | ₩81B | ₩73B | ₩54B | ₩55B |
| Borrowings | — | ₩39B | ₩39B | ₩38B | ₩39B | ₩44B |
| Total equity | ₩133B | ₩134B | ₩131B | ₩130B | ₩128B | ₩125B |
| Shareholders' equity | ₩133B | ₩134B | ₩131B | ₩130B | ₩128B | ₩125B |
Cash flow
| Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | |
|---|---|---|---|---|---|---|
| Cash from operations | ₩3.5B | ₩3B | ₩643M | ₩1.2B | ₩255M | −₩1.7B |
| Capital spending | ₩4.7B | −₩1.5B | ₩358M | ₩3.6B | ₩858M | ₩827M |
| Free cash flow | −₩1.2B | ₩1.5B | ₩285M | −₩2.5B | −₩603M | −₩2.5B |
Consolidated where available. Amounts in won.
Also known as: DongKook Life Science / 동국생명과학 / 303810 / KRX:303810
Source: KRX statistical information